Sam Osman is the CEO of Endpoint Clinical and Group CEO of Neovance, boasting a strong record of product launches and successful turnarounds in the technology and life sciences industries. They have been involved in key leadership roles and board positions, including their recent tenure as CEO at Cenduit and as a board member at multiple organizations. Sam's experience encompasses global leadership, operational restructuring, and high-performance team building, with a proven impact on sales growth exceeding $50 million in under 36 months. They hold an MBA from Carnegie Mellon University and have pursued executive education at The Wharton School, among other prestigious institutions.
This person is not in any teams